

GLAXOSMITHKLINE PLC
Form 6-K
March 23, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 23 March 2017

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Dr K Slaoui
 - b) Position/status PCA of Dr M M Slaoui
(Chairman, Global Vaccines)
 - c) Initial notification / amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument American Depositary Shares
(‘ADSs’)
 - b) Nature of the transaction ISIN: US37733W1053
An increase of 4 ADSs
following the notional
allocation of ADSs on 22
March 2017, at a price of
\$42.28 per ADS, as a result
of the revaluation of the cash
element of the notional
investment held within the
GSK 401(K) plan.
Price(s) Volume(s)
 - c) Price(s) and volume(s)

\$42.28 4

Aggregated information

- | | |
|-----------------------------|--------------------------|
| d) Aggregated volume | n/a (single transaction) |
| Price | |
| e) Date of the transaction | 2017-03-22 |
| f) Place of the transaction | n/a |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: March 23, 2017

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc